Insider Transactions in Q3 2022 at Xenon Pharmaceuticals Inc. (XENE)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,355
-100.0%
|
$598,845
$39.57 P/Share
|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,293
-17.66%
|
$128,427
$39.53 P/Share
|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,648
+19.95%
|
$111,888
$6.64 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
43,879
-46.09%
|
$1,667,402
$38.41 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
6,121
-9.16%
|
$232,598
$38.81 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+42.81%
|
$200,000
$4.75 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
21,352
-55.97%
|
$811,376
$38.57 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
1,572
-3.96%
|
$58,164
$37.86 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
22,488
+22.34%
|
$67,464
$3.71 P/Share
|
|
Aug 16
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
52,058
-66.07%
|
$1,978,204
$38.58 P/Share
|
|
Aug 15
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
33,942
-36.89%
|
$1,255,854
$37.76 P/Share
|
|
Aug 12
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
91,135
-19.4%
|
$3,463,130
$38.55 P/Share
|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Open market or private sale
|
Direct |
57,743
-60.79%
|
$2,194,234
$38.38 P/Share
|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
7,257
-9.68%
|
$275,766
$38.02 P/Share
|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+38.75%
|
$195,000
$3.93 P/Share
|